Sfrowasa (Mesalamine) Patent Expiration, LOE Window & CMS Spending

Sfrowasa (Mesalamine) by Viatris: FDA Orange Book core substance LOE 2027-07-24, 4 AB generics, $241K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN019618 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-07-24
Last Listed Patent or Exclusivity Date2027-07-24
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$241K
2024 Medicare Part D Spend$32K
2024 Medicaid Spend$209K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.